US2004131655A1PendingUtilityA1

Ophthalmic drug delivery device

Priority: Oct 21, 1999Filed: Oct 30, 2003Published: Jul 8, 2004
Est. expiryOct 21, 2019(expired)· nominal 20-yr term from priority
Inventors:Yoseph Yaacobi
A61K 9/0051A61F 9/00781A61F 9/0017A61F 2250/0067A61F 2009/00891A61F 2/14
63
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention is directed to a drug delivery device for a human eye. The human eye has a sclera, an inferior oblique muscle, and a macula. The device of the present invention includes a pharmaceutically active agent, and a geometry that facilitates the implantation of the device on an outer surface of the sclera, beneath the inferior oblique muscle, and with the pharmaceutically active agent disposed above the macula. Methods of delivery a pharmaceutically active agent to the posterior segment of the human eye are also disclosed.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . An ophthalmic drug delivery device, comprising: 
 a body having a scleral surface for placement proximate a sclera and a well having an opening to said scleral surface; and    an inner core disposed in said well comprising a pharmaceutically active agent, wherein said pharmaceutically active agent comprises nepafenac.    
     
     
         2 . An ophthalmic drug delivery device, comprising: 
 a body having a scleral surface for placement proximate a sclera and a well having an opening to said scleral surface; and    an inner core disposed in said well comprising a pharmaceutically active agent, wherein said pharmaceutically active agent comprises a cyclooxygenase inhibitor.    
     
     
         3 . The ophthalmic drug delivery device of  claim 2  wherein said pharmaceutically active agent is a Cox I inhibitor.  
     
     
         4 . The ophthalmic drug delivery device of  claim 2  wherein said pharmaceutically active agent is a Cox II inhibitor.

Join the waitlist — get patent alerts

Track US2004131655A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.